TERN
Terns Pharmaceuticals, Inc.Company Information
- Company Name
- Terns Pharmaceuticals, Inc.
- CIK
- CIK0001831363
- Category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Ticker: Exchange
- TERN: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- TERN
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-06-27
- Last sale
- 2026-04-01
- Shares purchased (TTM)
- 38,314
- Shares sold (TTM)
- 198,620
Institutional Sentiment
- As of
- 2026-03-31
- Institutional shares owned
- 115,573,712
- Shares outstanding
- 93,166,571
- Ownership
- 124.05%
Earnings Market Reaction
- Filing date
- 2026-03-30
- Price on filing date
- —
- 1-month reaction
- 0.02%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 525 | 151 | 146 | 139 | 161 | 270 | 91 | 65 | 80 | 38 | 81 | 184 | ||||||
| Marketable Securities Current | 494 | 145 | 169 | 195 | 197 | 103 | 134 | 176 | 184 | 229 | 205 | 113 | ||||||
Assets Current | ||||||||||||||||||
| Assets Current | 1,024 | 300 | 319 | 338 | 362 | 377 | 230 | 246 | 267 | 270 | 288 | 300 | ||||||
| Prepaid Expense And Other Assets Current | 5 | 5 | 4 | 3 | 4 | 4 | 5 | 5 | 4 | 4 | 3 | 2 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | ||||||
| Operating Lease Right Of Use Asset | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 1,025 | 302 | 320 | 339 | 364 | 378 | 231 | 247 | 269 | 272 | 290 | 301 | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||||
| Accounts Payable Current | 2 | 3 | 3 | 3 | 2 | 2 | 2 | 2 | 3 | 3 | 6 | 3 | ||||||
Liabilities Current | ||||||||||||||||||
| Liabilities Current | 16 | 15 | 13 | 11 | 16 | 11 | 11 | 9 | 12 | 12 | 14 | 12 | ||||||
| Operating Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | ||||||
| Accrued Income Taxes Noncurrent | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Operating Lease Liability Noncurrent | 0 | 1 | 1 | 1 | 1 | 1 | - | - | 0 | 0 | 0 | 0 | ||||||
| Liabilities | 19 | 18 | 15 | 13 | 18 | 14 | 12 | 10 | 13 | 13 | 16 | 14 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 1,524 | 778 | 775 | 771 | 768 | 764 | 597 | 592 | 588 | 571 | 557 | 552 | ||||||
Stockholders Equity | ||||||||||||||||||
| Stockholders Equity | 1,007 | 284 | 305 | 326 | 346 | 364 | 219 | 237 | 255 | 258 | 274 | 288 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | 0 | 0 | -0 | 0 | -0 | 0 | -0 | -0 | -0 | -1 | -1 | -0 | ||||||
| Retained Earnings Accumulated Deficit | -518 | -494 | -469 | -445 | -421 | -400 | -378 | -355 | -333 | -312 | -282 | -264 | ||||||
| Liabilities And Stockholders Equity | 1,025 | 302 | 320 | 339 | 364 | 378 | 231 | 247 | 269 | 272 | 290 | 301 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | ||||||
| Common Stock Shares Issued | 112 | 88 | 87 | 87 | 87 | 85 | 70 | 65 | 65 | 62 | 61 | 57 | ||||||
| Shares Outstanding | 112 | 88 | 87 | 87 | 87 | 85 | 70 | 65 | 65 | 62 | 61 | 57 | ||||||
Select a line item above to chart it.
Recent filings
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialTerns Pharmaceuticals, Inc. (TERN) — SEC Financial Statements & Analysis
Terns Pharmaceuticals, Inc. (TERN) is a pharmaceutical preparations company, incorporated in DE. Terns Pharmaceuticals, Inc. trades on Nasdaq as: TERN. Terns Pharmaceuticals, Inc. (TERN)'s most recent SEC filing is a Form 10-K for the period ended 2025-12-31, filed with the SEC on 2026-03-30. Based on its latest SEC filing (Form 10-Q, period ending 2025-12-31), On profitability, Terns Pharmaceuticals, Inc. posts a Return on Equity (ROE) of -14.23%, a Return on Assets (ROA) of -13.85%, and a Return on Invested Capital (ROIC) of -32.86%. Per share, it reports EPS of $-1.03, diluted EPS of $-1.03, free cash flow per share of $-0.88, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 8.28% year-over-year and EPS growth of -7.60% year-over-year. On the balance sheet, it maintains a current ratio of 62.41x, a quick ratio of 62.09x, working capital of $1.01B, a debt-to-equity ratio of 0.02x, a debt ratio of 0.02, free cash flow of $-82.18M (TTM), and net debt of $-524.75M. Figures sourced from SEC EDGAR.
- EPS TTM
- $-1.03
- ROE TTM
- -14.23%
- ROA TTM
- -13.85%
- Debt To Equity
- 0.02x
- Free Cash Flow TTM
- $-82.18M
Data as of 2025-12-31 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Terns Pharmaceuticals, Inc. in?
Terns Pharmaceuticals, Inc. (TERN) operates in the Pharmaceutical Preparations industry.
What exchange does TERN trade on?
Terns Pharmaceuticals, Inc. (TERN) trades on the Nasdaq.
Where is Terns Pharmaceuticals, Inc. incorporated?
Terns Pharmaceuticals, Inc. is incorporated in DE.
When was Terns Pharmaceuticals, Inc. (TERN)'s most recent SEC filing?
Terns Pharmaceuticals, Inc. (TERN)'s most recent SEC filing is a Form 10-K for the period ended 2025-12-31, filed with the SEC on 2026-03-30.
What is TERN's EPS (earnings per share)?
Terns Pharmaceuticals, Inc. (TERN)'s trailing twelve month EPS is $-1.03 as of 2025-12-31.
What is TERN's ROE (return on equity)?
Terns Pharmaceuticals, Inc. (TERN)'s trailing twelve month Return on Equity (ROE) is -14.23% as of 2025-12-31.
What is TERN's ROA (return on assets)?
Terns Pharmaceuticals, Inc. (TERN)'s trailing twelve month Return on Assets (ROA) is -13.85% as of 2025-12-31.
What is TERN's ROIC (return on invested capital)?
Terns Pharmaceuticals, Inc. (TERN)'s trailing twelve month Return on Invested Capital (ROIC) is -32.86% as of 2025-12-31.